A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

Lance C. Pagliaro, Ebrahim S. Delpassand, Dallas Williams, Randall E. Millikan, Shi Ming Tu, Christopher J. Logothetis

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma. METHODS. Patients with androgen-independent prostate carcinoma and painful osteoblastic bone metastases were eligible. On a 12-week course, patients received gemcitabine (600 mg/m2 or 800 mg/m2) on Days 1, 8, 15, 43, 50, and 57. A single dose of strontium-89 (55 μCi/kg) was administered on Day 8. RESULTS. Fifteen patients were registered, and all were assessable for response and toxicity. Four patients were treated at Dose Level I (gemcitabine 600 mg/m2) without dose-limiting toxicity. Eleven patients received a total of 13 courses at Dose Level 2 (gemcitabine 800 mg/m2). Platelet nadirs of 25,000-50,000 platelets per μL were common at Dose Level 2, and 1 patient had Grade 4 thrombocytopenia that was dose-limiting. Granulocyte nadirs up to < 500 granulocytes per μL occurred in 4 patients at Dose Level 2 and were reversible. There were no responses, as measured by prostate specific antigen concentration, although 6 patients (40%) had stable disease. CONCLUSIONS. The authors concluded that 800 mg/m2 gemcitabine was the maximum tolerated dose for the combination. The study was terminated on the basis that an overall response rate > than 10% was unlikely. Further study at this dose level and schedule is not warranted.

Original languageEnglish (US)
Pages (from-to)2988-2994
Number of pages7
JournalCancer
Volume97
Issue number12
DOIs
StatePublished - Jun 15 2003
Externally publishedYes

Fingerprint

gemcitabine
Strontium
Androgens
Prostate
Neoplasm Metastasis
Carcinoma
Bone and Bones
Therapeutics
Blood Platelets
Maximum Tolerated Dose
Granulocytes
Appointments and Schedules

Keywords

  • Bone-targeted therapy
  • Gemcitabine
  • Metastatic prostate carcinoma
  • Phase I clinical trial
  • Phase II clinical trial
  • Strontium-89

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. / Pagliaro, Lance C.; Delpassand, Ebrahim S.; Williams, Dallas; Millikan, Randall E.; Tu, Shi Ming; Logothetis, Christopher J.

In: Cancer, Vol. 97, No. 12, 15.06.2003, p. 2988-2994.

Research output: Contribution to journalArticle

Pagliaro, Lance C. ; Delpassand, Ebrahim S. ; Williams, Dallas ; Millikan, Randall E. ; Tu, Shi Ming ; Logothetis, Christopher J. / A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. In: Cancer. 2003 ; Vol. 97, No. 12. pp. 2988-2994.
@article{082ceffd87a0459392a9248967ba3503,
title = "A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases",
abstract = "BACKGROUND. The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma. METHODS. Patients with androgen-independent prostate carcinoma and painful osteoblastic bone metastases were eligible. On a 12-week course, patients received gemcitabine (600 mg/m2 or 800 mg/m2) on Days 1, 8, 15, 43, 50, and 57. A single dose of strontium-89 (55 μCi/kg) was administered on Day 8. RESULTS. Fifteen patients were registered, and all were assessable for response and toxicity. Four patients were treated at Dose Level I (gemcitabine 600 mg/m2) without dose-limiting toxicity. Eleven patients received a total of 13 courses at Dose Level 2 (gemcitabine 800 mg/m2). Platelet nadirs of 25,000-50,000 platelets per μL were common at Dose Level 2, and 1 patient had Grade 4 thrombocytopenia that was dose-limiting. Granulocyte nadirs up to < 500 granulocytes per μL occurred in 4 patients at Dose Level 2 and were reversible. There were no responses, as measured by prostate specific antigen concentration, although 6 patients (40{\%}) had stable disease. CONCLUSIONS. The authors concluded that 800 mg/m2 gemcitabine was the maximum tolerated dose for the combination. The study was terminated on the basis that an overall response rate > than 10{\%} was unlikely. Further study at this dose level and schedule is not warranted.",
keywords = "Bone-targeted therapy, Gemcitabine, Metastatic prostate carcinoma, Phase I clinical trial, Phase II clinical trial, Strontium-89",
author = "Pagliaro, {Lance C.} and Delpassand, {Ebrahim S.} and Dallas Williams and Millikan, {Randall E.} and Tu, {Shi Ming} and Logothetis, {Christopher J.}",
year = "2003",
month = "6",
day = "15",
doi = "10.1002/cncr.11412",
language = "English (US)",
volume = "97",
pages = "2988--2994",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

AU - Pagliaro, Lance C.

AU - Delpassand, Ebrahim S.

AU - Williams, Dallas

AU - Millikan, Randall E.

AU - Tu, Shi Ming

AU - Logothetis, Christopher J.

PY - 2003/6/15

Y1 - 2003/6/15

N2 - BACKGROUND. The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma. METHODS. Patients with androgen-independent prostate carcinoma and painful osteoblastic bone metastases were eligible. On a 12-week course, patients received gemcitabine (600 mg/m2 or 800 mg/m2) on Days 1, 8, 15, 43, 50, and 57. A single dose of strontium-89 (55 μCi/kg) was administered on Day 8. RESULTS. Fifteen patients were registered, and all were assessable for response and toxicity. Four patients were treated at Dose Level I (gemcitabine 600 mg/m2) without dose-limiting toxicity. Eleven patients received a total of 13 courses at Dose Level 2 (gemcitabine 800 mg/m2). Platelet nadirs of 25,000-50,000 platelets per μL were common at Dose Level 2, and 1 patient had Grade 4 thrombocytopenia that was dose-limiting. Granulocyte nadirs up to < 500 granulocytes per μL occurred in 4 patients at Dose Level 2 and were reversible. There were no responses, as measured by prostate specific antigen concentration, although 6 patients (40%) had stable disease. CONCLUSIONS. The authors concluded that 800 mg/m2 gemcitabine was the maximum tolerated dose for the combination. The study was terminated on the basis that an overall response rate > than 10% was unlikely. Further study at this dose level and schedule is not warranted.

AB - BACKGROUND. The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma. METHODS. Patients with androgen-independent prostate carcinoma and painful osteoblastic bone metastases were eligible. On a 12-week course, patients received gemcitabine (600 mg/m2 or 800 mg/m2) on Days 1, 8, 15, 43, 50, and 57. A single dose of strontium-89 (55 μCi/kg) was administered on Day 8. RESULTS. Fifteen patients were registered, and all were assessable for response and toxicity. Four patients were treated at Dose Level I (gemcitabine 600 mg/m2) without dose-limiting toxicity. Eleven patients received a total of 13 courses at Dose Level 2 (gemcitabine 800 mg/m2). Platelet nadirs of 25,000-50,000 platelets per μL were common at Dose Level 2, and 1 patient had Grade 4 thrombocytopenia that was dose-limiting. Granulocyte nadirs up to < 500 granulocytes per μL occurred in 4 patients at Dose Level 2 and were reversible. There were no responses, as measured by prostate specific antigen concentration, although 6 patients (40%) had stable disease. CONCLUSIONS. The authors concluded that 800 mg/m2 gemcitabine was the maximum tolerated dose for the combination. The study was terminated on the basis that an overall response rate > than 10% was unlikely. Further study at this dose level and schedule is not warranted.

KW - Bone-targeted therapy

KW - Gemcitabine

KW - Metastatic prostate carcinoma

KW - Phase I clinical trial

KW - Phase II clinical trial

KW - Strontium-89

UR - http://www.scopus.com/inward/record.url?scp=0037672705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037672705&partnerID=8YFLogxK

U2 - 10.1002/cncr.11412

DO - 10.1002/cncr.11412

M3 - Article

C2 - 12784333

AN - SCOPUS:0037672705

VL - 97

SP - 2988

EP - 2994

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -